Literature DB >> 1757242

Acute pyridostigmine overdose: a report of nine cases.

S Almog1, E Winkler, Y Amitai, S Dani, M Shefi, M Tirosh, J Shemer.   

Abstract

Pyridostigmine is known as a pre-treatment drug against intoxication with organophosphorus nerve agents. During the Persian Gulf war, we encountered a cluster of nine cases of pyridostigmine self-poisoning, of which three presented with mixed drug poisoning. The clinical and laboratory features of pyridostigmine toxicity are presented. Doses ranged between 390 and 900 mg. Pyridostigmine ingestion resulted in mild to moderate cholinergic symptoms such as abdominal cramps, diarrhea, emesis, nausea, hypersalivation, urinary incontinence, fasciculations, muscle weakness and blurred vision. No central nervous system manifestations were evident. The symptoms developed within several minutes and lasted up to 24 h. All patients underwent gastric emptying followed by administration of activated charcoal. Atropine (1-8 mg) was required in only three patients. Measurement of serum cholinesterase inhibition was found to be a reliable and sensitive diagnostic tool in pyridostigmine poisoning. No clear correlation was found between the extent of cholinesterase inhibition and the incidence or severity of the cholinergic signs. The clinical recovery was faster than the spontaneous recovery of the enzyme. Pyridostigmine intoxication is self-limited and well tolerated by young healthy adults.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1757242

Source DB:  PubMed          Journal:  Isr J Med Sci        ISSN: 0021-2180


  3 in total

1.  Feeling cold after donepezil.

Authors:  Subha Thiyagesh; Claire Young; Sean Spence
Journal:  J R Soc Med       Date:  2004-07       Impact factor: 18.000

2.  Pyridostigmine Suicidal Attempt in a Myasthenia Gravis Patient.

Authors:  Mohammed Aref T Malabaey; Ahad A Al-Saud; Yasser A Alaska; Afnan Almas; Almas Malik
Journal:  Am J Case Rep       Date:  2019-09-26

3.  A parallel-group, multicenter randomized, double-blinded, placebo-controlled, phase 2/3, clinical trial to test the efficacy of pyridostigmine bromide at low doses to reduce mortality or invasive mechanical ventilation in adults with severe SARS-CoV-2 infection: the Pyridostigmine In Severe COvid-19 (PISCO) trial protocol.

Authors:  Sergio Fragoso-Saavedra; David A Iruegas-Nunez; Alejandro Quintero-Villegas; H Benjamín García-González; Isaac Nuñez; Sergio L Carbajal-Morelos; Belem M Audelo-Cruz; Sarahi Arias-Martínez; Yanink Caro-Vega; Juan José Calva; Verónica Luqueño-Martínez; Alejandra González-Duarte; Brenda Crabtree-Ramírez; José C Crispín; Juan Sierra-Madero; Pablo F Belaunzarán-Zamudio; Sergio I Valdés-Ferrer
Journal:  BMC Infect Dis       Date:  2020-10-16       Impact factor: 3.090

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.